The specific anti-glycosylated PD-L1 (gPD-L1) antibody could target glycosylated PD-L1, resulting in PD-L1 degradation; thus, the conjugated STM108 (anti-gPD-L1) with MMAE (monomethyl auristatin E) effectively enhances antitumor activity in a breast tumor model31. This evidence concerns the gene CD274 and breast neoplasm.